Lung cancer biomarker testing trial sees drop in deaths

Biomarker testing in individuals at risk of lung cancer led to a major reduction in deaths, new research reveals.

© National Cancer Institute/Unsplash

© National Cancer Institute/Unsplash

The University of St Andrews School of Medicine study, conducted with 12,000 smokers and ex-smokers, demonstrates how biomarkers - measurable indicators of biological changes - can identify individuals at high risk of lung cancer, leading to earlier detection and significantly improved outcomes.

The study, published in PLoS ONE, found that testing high-risk individuals with biomarkers led to a 40% reduction in deaths from lung cancer and other causes over five years.

The research team aims to explore how biomarker testing could enhance lung cancer screening programs currently being developed or implemented in several countries. This targeted strategy could improve the identification of individuals most at risk, ensuring that screening resources are used efficiently and effectively.

Dr Frank Sullivan, professor of primary care medicine at the University of St Andrews School of Medicine, said: ‘This study, along with others using imaging techniques, shows that earlier diagnosis of lung cancer is now possible. That is good news because, if caught early enough, the improved treatments now available have a much higher chance of success.'

Study to shed light on youth vaping

Study to shed light on youth vaping

By Liz Wells 19 February 2025

A £62m research project is to investigate long-term health effects of vaping on young people's health and wellbeing, alongside wider influences on adolescent...

AI trial to tackle breast cancer launched

By Liz Wells 04 February 2025

Nearly 700,000 women across the country will take part in a trial to test how AI tools can be used to catch breast cancer cases earlier, the DHSC has announced.

PocDoc and Well rollout at-home test for cardiovascular disease

By Liz Wells 03 February 2025

PocDoc, the digital health diagnostics company, is partnering with pharmacy chain Well to launch its at-home cardiovascular disease (CVD) test in its pharmac...


Popular articles by Liz Wells